Tuesday - April 28, 2026

Category Archives: Marketing & Sales

HER2-Negative Breast Cancer Pipeline Accelerates as 70+ Pharma Companies Advance Novel Breast Cancer Therapies, Finds DelveInsight | Merck Sharp & Dohme LLC, AstraZeneca, Roche, Genentech

HER2-Negative Breast Cancer – Pipeline Insight, 2026 There are 70+ key companies, including Merck Sharp & Dohme LLC, AstraZeneca, Roche, Genentech, Daiichi Sankyo, Novartis, Beijing Biotech, and Regor Therapeutics, developing therapies for HER2-Negative Breast Cancer, with AstraZeneca leading with advanced … Continue reading →

Endometrial Cancer Pipeline Grows as 50+ Pharma Companies Advance Novel Gynecologic Cancer Therapies, Finds DelveInsight | Selinexor, Abemaciclib, NP137, CT-0508

Endometrial Cancer – Pipeline Insight, 2026 There are over 50 key companies, including Karyopharm Therapeutics, Eli Lilly, Netris Pharma, Incyte Corporation, and others, developing therapies for Endometrial Cancer, with several candidates now in advanced Phase III and Phase II stages … Continue reading →

Treatment Resistant Depression Pipeline Grows as 25+ Pharma Companies Advance Novel Mental Health Therapies, Finds DelveInsight | Axsome Therapeutics, COMPASS Pathways, Janssen Pharmaceuticals

Treatment Resistant Depression (TRD) – Pipeline Insight, 2026 There are 25+ key companies, including Janssen Pharmaceuticals, Merck, Novartis, Sage Therapeutics, Axsome Therapeutics, and COMPASS Pathways, developing therapies for Treatment Resistant Depression, with several novel-mechanism drugs currently in Phase III clinical … Continue reading →

Clostridium Difficile Infections Pipeline Set for Transformational Growth by 2026 with 22+ Therapies and Strong Clinical Momentum from Vedanta Biosciences, Acurx Pharmaceuticals | DelveInsight

Clostridium Difficile Infections Clinical Trial Key Clostridium Difficile Infections Companies are Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics, Vedanta Biosciences, and others. Clostridium Difficile Infections (CDI) therapeutics are entering a new era of innovation and clinical acceleration, driven by … Continue reading →

Non-Cystic Fibrosis Bronchiectasis Pipeline Set for Significant Expansion by 2026 with 12+ Therapies and Robust Clinical Progress from Haisco Pharmaceutical, CSL Behring, Insmed, Zambon | DelveInsight

Non-Cystic Fibrosis Bronchiectasis Clinical Trials Key Non-Cystic Fibrosis Bronchiectasis Companies are Zambon SpA, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring, and others. The Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutic landscape is witnessing a strong wave of … Continue reading →

Diabetic Retinopathy Pipeline Set for Transformational Breakthroughs by 2026 with 55+ Therapies expanding Clinical Innovation from Kodiak Sciences, Regenxbio, Adverum Biotechnologies | DelveInsight

Diabetic Retinopathy Clinical Trial Key Diabetic Retinopathy Companies are Kodiak Sciences, RemeGen, Vantage Biosciences Ltd, Apexian Pharmaceuticals, Ocular Therapeutix, Regenxbio, Adverum Biotechnologies, Therini Bio Pty Ltd, and others The Diabetic Retinopathy therapeutic landscape is undergoing a significant evolution, driven by … Continue reading →

Huntington’s Disease Pipeline Set for Breakthrough Transformation by 2026 with 20+ Therapies and Advancing Gene-Silencing Innovations | DelveInsight

Huntington’s Disease Clinical Trial Key Huntington’s Disease Companies are Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio, and others. Huntington’s Disease Pipeline Set for Breakthrough Transformation by 2026 with 20+ Therapies and Advancing Gene-Silencing Innovations from Hoffmann-La Roche, … Continue reading →